San Raffaele Vita-Salute University, Milan, Italy.
Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Cancer Res. 2019 Apr 15;79(8):1925-1937. doi: 10.1158/0008-5472.CAN-18-0289. Epub 2019 Feb 22.
The unbalanced production of pro- and antiangiogenic factors in tumors can lead to aberrant vasculature morphology, angiogenesis, and disease progression. In this study, we report that disease progression in various murine models of solid tumors is associated with increased cleavage of full-length chromogranin A (CgA), a circulating vasoregulatory neurosecretory protein. Cleavage of CgA led to the exposure of the highly conserved PGPQLR site, which corresponds to residues 368-373 of human CgA, a fragment that has proangiogenic activity. Antibodies against this site, unable to bind full-length CgA, inhibited angiogenesis and reduced tumor perfusion and growth. The PGPQLR sequence of the fragment, but not of the precursor, bound the VEGF-binding site of neuropilin-1; the C-terminal arginine (R) of the sequence was crucial for binding. The proangiogenic activity of the CgA was blocked by anti-neuropilin-1 antibodies as well as by nicotinic acetylcholine receptor antagonists, suggesting that these receptors, in addition to neuropilin-1, play a role in the proangiogenic activity of CgA. The R residue was enzymatically removed in plasma, causing loss of neuropilin-1 binding and gain of antiangiogenic activity. These results suggest that cleavage of the RR site of circulating human CgA in tumors and the subsequent removal of R in the blood represent an important "on/off" switch for the spatiotemporal regulation of tumor angiogenesis and may serve as a novel therapeutic target. SIGNIFICANCE: This work reveals that the interaction between fragmented chromogranin A and neuropilin-1 is required for tumor growth and represents a novel potential therapeutic target.
肿瘤中促血管生成和抗血管生成因子的失衡会导致血管形态异常、血管生成和疾病进展。在这项研究中,我们报告说,各种实体瘤小鼠模型中的疾病进展与全长嗜铬粒蛋白 A(CgA)的切割增加有关,CgA 是一种循环血管调节神经分泌蛋白。CgA 的切割导致高度保守的 PGPQLR 位点暴露,该位点对应于人 CgA 的 368-373 位残基,是具有促血管生成活性的片段。针对该位点的抗体不能与全长 CgA 结合,可抑制血管生成并减少肿瘤灌注和生长。该片段的 PGPQLR 序列,但不是前体,与神经纤毛蛋白-1 的 VEGF 结合位点结合;序列的 C 末端精氨酸(R)对于结合至关重要。CgA 的促血管生成活性被抗神经纤毛蛋白-1 抗体以及烟碱型乙酰胆碱受体拮抗剂阻断,表明这些受体除了神经纤毛蛋白-1 外,还在 CgA 的促血管生成活性中发挥作用。CgA 中的 R 残基在血浆中被酶切,导致失去与神经纤毛蛋白-1 的结合并获得抗血管生成活性。这些结果表明,肿瘤中循环人 CgA 的 RR 位点的切割以及随后在血液中去除 R 代表了肿瘤血管生成时空调节的重要“开/关”开关,并可能成为一种新的治疗靶点。意义:这项工作揭示了片段化嗜铬粒蛋白 A 与神经纤毛蛋白-1 之间的相互作用是肿瘤生长所必需的,代表了一种新的潜在治疗靶点。